On August 29, 2023, the U.S. Department of Health and Human Services (HHS) recommended the DEA reclassify marijuana and move it from Schedule I to Schedule III, following a review by the Food and Drug Administration (FDA), as part of a process initiated by President Joe Biden in 2022.
"When President Biden ordered something here, we thought it would take a really long amount of time. But this is a big positive moment for cannabis as an industry as a whole," said George Archos, CEO of Verano Holdings Corp. (OTCQX: VRNOF).
Want to talk with the team of this leading multi-state cannabis company? Darren Weiss, Verano’s president, and Aaron Miles CIO are featured speakers at the upcoming Benzinga Cannabis Capital Conference in Chicago. Mark your calendar for September 27 and 28.
A Congressional Research Service (CRS) report suggested the DEA may lean towards the HHS's suggestion, given …